Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling

Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling

Summary: Hepatocellular carcinoma (HCC) remains one of the deadliest malignancies worldwide. One major obstacle to treatment is a lack of effective molecular-targeted therapies. In this study, we find that EphA2 expression and signaling are enriched in human HCC and associated with poor prognosis. L...

Full description

Bibliographic Details
Main Authors: Hao Wang, Wei Hou, Aldeb Perera, Carlee Bettler, Jordan R. Beach, Xianzhong Ding, Jun Li, Mitchell F. Denning, Asha Dhanarajan, Scott J. Cotler, Cara Joyce, Jun Yin, Fowsiyo Ahmed, Lewis R. Roberts, Wei Qiu
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:Cell Reports
Subjects:
EphA2
HCC
AKT
STAT3
JAK1
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124721000784

Internet

http://www.sciencedirect.com/science/article/pii/S2211124721000784

Similar Items